Edge, SurModics to develop sustained-release NimoGel; FDA reviews Eisai's oral Banzel;

> Edge Therapeutics, based in Newark, NJ, and SurModics, based in Birmingham, AL, have entered into a feasability agreement to develop a novel biodegradable, site-specific, sustained-release formulation of NimoGel, Edge's lead drug for treatment of delayed complications of ruptured brain aneurysms or traumatic brain injury. Release

> Starting with carbon nanotubes, a team of researchers from the United Kingdom and Spain has developed a sugar-coated nanocapsule that can deliver large doses of radioactivity to tumors. They envision a series of nanoscale delivery devices that can target specific organs in the body for radiation therapy or imaging by tinkering with the sugar coating on the nanocapsule. Report

> The FDA has agreed to review Eisai's Banzel oral suspension for treating seizures. Banzel is available in a tablet, but some children and adults have trouble swallowing it. Report

And Finally... The most interesting logos in pharma. Slideshow

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.